Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Over 30 loci have been associated with risk of type 2 diabetes at genome-wide statistical significance. Genetic risk scores (GRSs) developed from these loci predict diabetes in the general population. We tested if a GRS based on an updated list of 34 type 2 diabetes–associated loci predicted progression to diabetes or regression toward normal glucose regulation (NGR) in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS: We genotyped 34 type 2 diabetes–associated variants in 2,843 DPP participants at high risk of type 2 diabetes from five ethnic groups representative of the U.S. population, who had been randomized to placebo, metformin, or lifestyle intervention. We built a GRS by weighting each risk allele by its reported effect size on type 2 diabetes risk and summing these values. We tested its ability to predict diabetes incidence or regression to NGR in models adjusted for age, sex, ethnicity, waist circumference, and treatment assignment. RESULTS: In multivariate-adjusted models, the GRS was significantly associated with increased risk of progression to diabetes (hazard ratio [HR] = 1.02 per risk allele [95% CI 1.00–1.05]; P = 0.03) and a lower probability of regression to NGR (HR = 0.95 per risk allele [95% CI 0.93–0.98]; P < 0.0001). At baseline, a higher GRS was associated with a lower insulinogenic index (P < 0.001), confirming an impairment in β-cell function. We detected no significant interaction between GRS and treatment, but the lifestyle intervention was effective in the highest quartile of GRS (P < 0.0001). CONCLUSIONS: A high GRS is associated with increased risk of developing diabetes and lower probability of returning to NGR in high-risk individuals, but a lifestyle intervention attenuates this risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hivert et al. (7) developed a 34-SNP T2D polygenic score. Similar to our β-cell cluster pPS findings, the authors determined that DPP participants in the highest T2D polygenic score quartile had reduced β-cell secretory response (IGR) at baseline compared with those in the lowest quartile; however, the 1-year longitudinal change in IGR was not significantly different between the two groups.”
From Increased genetic risk for β-cell failure is associated with β-cell function decline in people with prediabetes (2024) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · cited 1×
“C-statistic (28) and the integrated discrimination improvement (29) of the”
BackgroundThe Wellcome Trust Case Control Consortium, U.K.
Mossman, K. (2008) · Scientific American · doi:10.1038/scientificamerican0108-42a · Cited by 2,684
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
DIAGRAM Consortium, Dupuis, J., GIANT Consortium, Global BPgen Consortium, Anders Hamsten on behalf of Procardis Consortium, the MAGIC investigators, Langenberg, C., Prokopenko, I., Saxena, R., Soranzo, N., et al. (2010) · Nature Genetics · doi:10.1038/ng.520 · Cited by 2,166
Self-citationWellcome Trust Case Control Consortium, Zeggini, E., Scott, L. J., Saxena, R., Voight, B. F., Marchini, J. L., Hu, T., de Bakker, P. I., Abecasis, G. R., Almgren, P., et al. (2008) · Nature Genetics · doi:10.1038/ng.120 · Cited by 1,864
Self-citationTwelve type 2 diabetes susceptibility loci identified through large-scale association analysis
The MAGIC investigators, Voight, B. F., The GIANT Consortium, Scott, L. J., Steinthorsdottir, V., Morris, A. P., Dina, C., Welch, R. P., Zeggini, E., Huth, C., et al. (2010) · Nature Genetics · doi:10.1038/ng.609 · Cited by 1,761
Self-citationPencina, M. J., & D'Agostino, R. B. (2004) · Statistics in Medicine · doi:10.1002/sim.1802 · Cited by 1,444 · cited 1×
“C-statistic (28) and the integrated discrimination improvement (29) of the”
BackgroundGreenland, P. (2008) · Statistics in Medicine · doi:10.1002/sim.2976 · Cited by 1,300
Clinical risk factors, DNA variants, and the development of type 2 diabetes
Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T., Berglund, G., Altshuler, D., Nilsson, P., & Groop, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801869 · Cited by 938
Self-citation
Cited by
Items 101–191 of 191
Predicting Diabetes: Our Relentless Quest for Genomic Nuggets
Dagogo-Jack, S. E. (2012) · Diabetes Care · doi:10.2337/dc11-2106 · Cited by 16
Prevalence of pre-diabetes in young Mexican adults in primary health care
Ureña-Bogarín, E. L., Martínez–Ramírez, H. R., Torres-Sánchez, J., Hernández-Herrera, A., Cortés–Sanabria, L., & Cueto-Manzano, A. M. (2014) · Family Practice · doi:10.1093/fampra/cmu047 · Cited by 19
An update on diagnosis and therapeutics for type-2 diabetes mellitus
Babu, S. (2023) · Bioinformation · doi:10.6026/97320630019295 · Cited by 16
Recent Research in the Genetics of Exercise Training Adaptation
Venezia, A. C., & Roth, S. M. (2016) · Medicine and sport science/Medicine and sport · doi:10.1159/000445239 · Cited by 17
McCaffery, J. M. (2018) · American Psychologist · doi:10.1037/amp0000253 · Cited by 16
“In the Diabetes Prevention Program (DPP; Knowler et al., 2002), 3,324 participants with impaired glucose tolerance were randomized to a placebo control, 850 mg of metformin twice daily or lifestyle intervention focusing on weight loss through calorie restriction, a low-fat diet, increased physical activity and support…”
MethodInfluentialType 2 diabetes: remission in just a week
Yki‐Järvinen, H. (2011) · Diabetologia · doi:10.1007/s00125-011-2266-6 · Cited by 14
“2 mmol/l), a healthy lifestyle can compensate for bad genes—as indeed has been shown for diabetes prevention [17].”
BackgroundHommos, N. A. A., Ebenibo, S., Edeoga, C., & Dagogo-Jack, S. E. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa164 · Cited by 15
Edeoga, C., Owei, I., Siwakoti, K., UMEKWE, N. A., Ceesay, F., Wan, J. Y., & Dagogo-Jack, S. E. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.07.019 · Cited by 15
2015 Presidential Address: 75 Years of Battling Diabetes−Our Global Challenge
Dagogo-Jack, S. E. (2015) · Diabetes Care · doi:10.2337/dc15-1818 · Cited by 13
Srinivasan, S., Jablonski, K. A., Knowler, W. C., Dagogo-Jack, S. E., Kahn, S. E., Boyko, E. J., Bray, G. A., Horton, E. S., Hivert, M., Goldberg, R. B., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00069 · Cited by 13
Self-citationLigthart, S., Hasbani, N. R., Ahmadizar, F., van Herpt, T. T. W., Leening, M. J. G., Uitterlinden, A. G., Sijbrands, E. J. G., Morrison, A. C., Boerwinkle, E., Pankow, J. S., et al. (2021) · Diabetic Medicine · doi:10.1111/dme.14639 · Cited by 14
Systematic evaluation of personal genome services for Japanese individuals
隆, 城., Kawashima, M., Nishino, S., Swan, M., Kamatani, N., & Butte, A. J. (2013) · Journal of Human Genetics · doi:10.1038/jhg.2013.96 · Cited by 13
Layton, J. C., Li, X., Shen, C., de Groot, M., Lange, L. A., Correa, A., & Wessel, J. (2018) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551417748942 · Cited by 15
Clinical use of polygenic scores in type 2 diabetes: challenges and possibilities
Prasad, R. B., Hakaste, L., & Tuomi, T. (2025) · Diabetologia · doi:10.1007/s00125-025-06419-1 · Cited by 19
“Obviously, individuals with a high genetic risk are not destined to develop type 2 diabetes, and protective lifestyle changes have been shown to attenuate the risk of diabetes in those with a high T2D-PGS [29, 30].”
Dankner, R. S., Bergman, M., Danoff, A., Qureshi, S., Whitford, I., Kaviani, N., Dynkevich, Y., & Roth, J. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2373 · Cited by 15
“Genetic susceptibility to type 2 diabetes typically adds little to readily obtained clinical measures for short-term disease prediction [14].”
BackgroundDauriz, M., Porneala, B., Guo, X., Bielak, L. F., Peyser, P. A., Durant, N. H., Carnethon, M. R., Bonadonna, R. C., Bonora, E., Bowden, D. W., et al. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000740 · Cited by 13
Self-citationBillings, L. K., Jablonski, K. A., Pan, Q., Florez, J. C., Franks, P. W., Goldberg, R. B., Hivert, M.-F., Kahn, S. E., Knowler, W. C., Lee, C. G., et al. (2024) · Diabetes · doi:10.2337/db23-0761 · Cited by 11
Self-citationMicroRNAs Associated With Incident Diabetes in the Diabetes Prevention Program
Flowers, E., Aouizerat, B. E., Kanaya, A. M., Florez, J. C., Gong, X., & Zhang, L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac714 · Cited by 11
Self-citationGautier, A., Roussel, R., Lange, C., Piguel, X., Cauchi, S., Vol, S., Froguel, P., Balkau, B., & Bonnet, F. (2011) · Diabetes · doi:10.2337/db10-1442 · Cited by 13
Szczerbiński, Ł., Gościk, J., Bauer, W., Wawrusiewicz‐Kurylonek, N., Paczkowska‐Abdulsalam, M., Niemira, M., Citko, A., Adamska-Patruno, E., Górska, M., & Kretowski, A. J. (2019) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.14866 · Cited by 19
Diagnostic Criteria and Classification of Diabetes
Leu, J. P., & Zonszein, J. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_7 · Cited by 20
Walker, C. G., Loos, R. J. F., Mander, A., Jebb, S. A., Frost, G. S., Griffin, B. A., Lovegrove, J. A., Sanders, T. A. B., & Bluck, L. J. C. (2012) · Genes & Nutrition · doi:10.1007/s12263-012-0284-8 · Cited by 13
“The effects of a combined GPS in the DPP are discussed above (Hivert et al. 2011).”
Proitsi, P., Lupton, M. K., Velayudhan, L., Hunter, G., Newhouse, S., Lin, K., Fogh, I., Tsolaki, M., Daniilidou, M., Pritchard, M., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.023 · Cited by 11
“…T2DM prevalence of 8% (compared with 5.7% explained by the 63 autosomal SNPs re-ported by Morris et al., 2012) and include most of those previously used in T2DM genetic risk score analyses (Andersson et al., 2013; Cornelis et al., 2009; Hivert et al., 2011; Lango et al., 2008; Meigs et al., 2008).”
InfluentialUsing Personalized Medicine in the Management of Diabetes Mellitus
Elk, N., & Iwuchukwu, O. F. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1976 · Cited by 12
“The Framingham Heart Study (FHS) and the DPP are representative cohorts that have successfully used this approach to predict diabetes risk.(83,84) In the FHS, a GRS based on 18 risk alleles predicted new cases of diabetes with a slightly better prediction of risk than”
BackgroundMethodInfluentialGenetic and clinic predictors of new onset diabetes mellitus after transplantation
Study, T. S. T. C., Saigí-Morgui, N., Quteineh, L., Bochud, P., Crettol, S., Kutalik, Z., Mueller, N. J., Binet, I., van Delden, C., Steiger, J. U., et al. (2017) · The Pharmacogenomics Journal · doi:10.1038/s41397-017-0001-5 · Cited by 10
“some of the results were further replicated [13, 14].”
Hornbak, M., Allin, K. H., Jensen, M. L., Lau, C. J., Witte, D. R., Jørgensen, M. E., Sandbæk, A., Lauritzen, T., Andersson, Å., Pedersen, O. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104837 · Cited by 9
Genomic-based tools for the risk assessment, management, and prevention of type 2 diabetes
Taber, K. J., & Dickinson, B. D. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s75583 · Cited by 16
Genetic studies of type 2 diabetes, and microvascular complications of diabetes
Imamura, M., & Maeda, S. (2024) · Diabetology International · doi:10.1007/s13340-024-00727-4 · Cited by 9
“Previous investigations have indicated that lifestyle interventions can mitigate the genetic risk defined by carrying variants linked to T2D [66, 67].”
Can Genetic Information Change Patient Behavior to Reduce Type 2 Diabetes Risk?
Vassy, J. L. (2012) · Personalized Medicine · doi:10.2217/pme.12.116 · Cited by 8
Wu, Y. Y., Thompson, M. D., Youkhana, F., & Pirkle, C. M. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab025 · Cited by 10
Franceschini, N., Haack, K., Göring, H. H. H., Voruganti, V. S., Laston, S., Almasy, L. A., Lee, E. T., Best, L. G., Fabsitz, R. R., North, K. E., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2988-8 · Cited by 8
“The underlying mechanisms leading to progression to type 2 diabetes are not fully elucidated [21], with a critical barrier being the small number of prospective studies.”
Self-citationOn the Verge of Precision Medicine in Diabetes
Li, J. H., & Florez, J. C. (2022) · Drugs · doi:10.1007/s40265-022-01774-4 · Cited by 9
Self-citationGenome-Wide Association Studies of Type 2 Diabetes
SLADEK, R. M., & Prokopenko, I. (2016) · Springer eBooks · doi:10.1007/978-3-319-01574-3_2 · Cited by 7
“Similarly, Hivert et al. have shown that a GRS with 34 variants was significantly associated with increased risk of progression to T2D in high-risk individuals, as well as a reduced effect of lifestyle interventions on genetic risk (Hivert et al. 2011).”
BackgroundResultPrimary Prevention of Type 2 Diabetes: An Imperative for Developing Countries
Dagogo-Jack, S. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-41559-8_2 · Cited by 8
Martono, D. P., Heerspink, H. J. L., Hak, E., Denig, P., & Wilffert, B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13803 · Cited by 7
Epidemiology and Risk Factors of Type 2 Diabetes
Ley, S. H., & Meigs, J. B. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_5-1 · Cited by 7
Self-citationThe Continuing Evolution of Precision Health in Type 2 Diabetes: Achievements and Challenges
Lin, Y., & Wessel, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1137-2 · Cited by 7
Genetics, Genomics and Personalized Medicine in Type 2 Diabetes: A Perspective on the Arab Region
Siddiqui, K., & Tyagi, S. (2015) · Personalized Medicine · doi:10.2217/pme.15.11 · Cited by 7
Franks, P. W. (2012) · Diabetologia · doi:10.1007/s00125-012-2683-1 · Cited by 5
“Findings from several prospective cohort studies [4–6] and clinical trials [7] of older adults have been published that document the predictive accuracy of type 2 diabetes genetic risk scores and compared these with conventional and complex non-genetic risk prediction algorithms.”
BackgroundSelf-citationHeianza, Y., & Qi, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00029-1 · Cited by 6
Scales for assessing the genetic risk of developing type 2 diabetes mellitus
Kurilova, O. V., Kiseleva, A. V., Meshkov, A. N., Сотникова, Е. А., Ershova, A. I., Иванова, А. А., Limonova, A. S., & Drapkina, O. M. (2021) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202124121115 · Cited by 7
Knüppel, S., Meidtner, K., Arregui, M., Holzhütter, H., & Boeing, H. (2015) · Annals of Human Genetics · doi:10.1111/ahg.12115 · Cited by 4
Razavi, L. N., Ebenibo, S., Edeoga, C., Wan, J., & Dagogo-Jack, S. (2020) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2020.03.005 · Cited by 4
Anticipation of Precision Diabetes and Promise of Integrative Multi-Omics
Liu, C., & Sun, Y. V. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.011 · Cited by 4
Epidemiology and Risk Factors of Type 2 Diabetes
Ley, S. H., & Meigs, J. B. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_5 · Cited by 11
Self-citationSchulze, M. B., & Hu, F. B. (2022) · Springer eBooks · doi:10.1007/978-1-4614-6625-3_66-1 · Cited by 6
Diagnostic Criteria and Classification of Diabetes
Gospin, R., Leu, J. P., & Zonszein, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_7-2 · Cited by 6
KORA-Studie: Ergebnisse aus 20 Jahren Gesundheitsforschung in Augsburg
Kirchberger, I., & Meisinger, C. (2012) · Public Health Forum · doi:10.1016/j.phf.2012.06.010 · Cited by 3
“…unter Beteiligung der KORA Herzinfarkt- und Typ-2Diabetes-Fälle und Kontrollen durchgeführt, im Rahmen der CARDIOGENICS, CARDIOGRAM, DIAGRAM and MAGIC Konsortien (Schunkert et al., 2011; Voight et al., 2010; Dupuis et al., 2010; Qi et al., 2010; de MiguelYanes et al., 2011; Hivert et al., 2011).”
BackgroundGrant, S. F. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_11-1 · Cited by 3
Florez, J. C., Udler, M. S., & Hanson, R. L. (2021) · Europe PMC (PubMed Central) · Cited by 6
Self-citationGrant, S. F. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_11 · Cited by 4
The Role of Pharmacogenomics in Diabetes
Lam, Y. W. F., Duggirala, R., Jenkinson, C. P., & Arya, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812626-4.00009-7 · Cited by 4
The Role of Pharmacogenomics in Diabetes, HIV Infection, and Pain Management
Aquilante, C. L., & Lam, Y. W. F. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391918-2.00007-x · Cited by 2
Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers
Moura, F. A., Kamanu, F., Wiviott, S. D., Giugliano, R. P., Udler, M. S., Florez, J. C., Ellinor, P. T., Sabatine, M. S., Ruff, C. T., & Marston, N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16123 · Cited by 2
“17 There is the potential to leverage PGS risk stratification for T2D to identify high genetic risk individuals who do not have traditional clinical risk factors, for a clinical trial to determine whether earlier intervention is effective in preventing the development of diabetes.”
Self-citationFojas, E. G., Haidery, A., Naseeb, S., & Naemi, R. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109003 · Cited by 3
Diagnostic Criteria and Classification of Diabetes
Gospin, R., & Zonszein, J. (2015) · Springer eBooks · doi:10.1007/978-3-319-20797-1_7-1 · Cited by 2
Common Mutations and Polymorphisms Predicting Adverse Cardiovascular Events: Current View
Visvikis‐Siest, S., Stathopoulou, M. G., & Ndiaye, N. C. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.167 · Cited by 2
Barzilay, J. I., Lai, D., Davis, B. R., Pressel, S., Previn, H. E., & Arnett, D. K. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy199 · Cited by 2
Le diabete de type 2: voyage au coeur d'une maladie complexe.
Scheen, A. J., & Paquot, N. (2012) · RMLG. Revue médicale de Liège · Cited by 2
Diagnostic Criteria and Classification of Diabetes
Gospin, R., Leu, J. P., & Zonszein, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_7 · Cited by 7
Grant, S. F. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_11 · Cited by 3
Clinical Implementation of Genomic Medicine in Primary Care
Cho, A. H., & Orlando, L. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382227-7.00025-2 · Cited by 2
Genome-Wide Association Study for Type 2 Diabetes
Imamura, M., Horikoshi, M., & Maeda, S. (2019) · Springer eBooks · doi:10.1007/978-981-13-8177-5_4 · Cited by 2
Effect of Three-Component Interactions Among Starch, Lipids and Proteins on the Glycemic Response
Parada, J., & Santos, J. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-100596-5.21518-7 · Cited by 2
Genetics of Drug Response in Diabetes
Pearson, E. R., & Florez, J. C. (2014) · Frontiers in diabetes · doi:10.1159/000362475 · Cited by 1
Self-citationValeeva, F. V., Khasanova, K. B., Валерьевна, В. Е., Киселева, Т. А., & Рамилевна, И. Д. (2023) · Aspirantskiy Vestnik Povolzhiya · doi:10.55531/2072-2354.2023.23.1.47-56 · Cited by 1
Jones, B., Pengelly, R. J., Borthwick, A., & Bowen, C. J. (2025) · Journal of Foot and Ankle Research · doi:10.1002/jfa2.70062
Gene-Environment Interaction and Individual Susceptibility to Metabolic Disorders
Dahlman, I. A., & Rydén, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-35213-4_5 · Cited by 1
Precision medicine in diabetes - current trends and future directions. Is the future now?
Szczerbiński, Ł., & Florez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00021-6 · Cited by 1
Self-citationAcosta, T., Gabriel, R., & Tuomilehto, J. O. (2012) · Diabetes Management · doi:10.2217/dmt.12.9
Cuthbert, C. E., Ramdath, D. D., & Foster, J. E. (2014) · Lifestyle Genomics · doi:10.1159/000363138
Pretorius, J. (2012) · SUNScholar (Stellenbosch University)
Genomic science: what are the implications for personalized diabetes care?
Kant, R., & Silver, K. D. (2013) · Diabetes Management · doi:10.2217/dmt.13.7
Making a Meaningful Difference: Learning From People, Practice, and Research
Delahanty, L. M. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.1.58
Nutrigenetics of Type 2 Diabetes
Qi, L., & Franks, P. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-01574-3_26
Self-citationHivert, M., & Knowler, W. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-01574-3_25
Self-citationBodhini, D., Morton, R. W., Santhakumar, V., Nakabuye, M., Pomares‐Millan, H., Clemmensen, C., Fitzpatrick, S. L., Guasch‐Ferré, M., Pankow, J. S., Ried‐Larsen, M., et al. (2023) · medRxiv · doi:10.1101/2023.05.03.23289433
Self-citation2.2型糖尿病における進歩;ゲノムワイド関連解析による疾患感受性遺伝子領域同定の成果
今村美菜子, & 士郎, 前. (2014) · 糖尿病 · doi:10.11213/tonyobyo.57.85
Assessment of multi-population polygenic risk scores for lipid traits in African Americans
Drouet, D. E., Liu, S., & Crawford, D. C. (2023) · PeerJ · doi:10.7717/peerj.14910
Grant, S. F. A. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_11-2
Udenze, I. C., Taiwo, I. A., Amadi, C. E., & Adeyemo, W. L. (2024) · International Journal of Advanced Medical and Health Research · doi:10.4103/ijamr.ijamr_187_23
Trends and challenges in managing diabetes mellitus-personalized medicine
Alaoufi, S. M., Alanazi, M. M., ALKhabbaz, G. G., Alharbi, Y. F., Almutairi, D. B., Almutairi, K. A., & Alamri, S. A. (2017) · International Journal of Health Sciences · doi:10.53730/ijhs.v1ns1.15130
Prediabetes: Insights from Genomics, Transcriptomics, microRNAs, Metabolomics, and Microbiomics
(2021) · American Diabetes Association eBooks · doi:10.2337/9781580407625.ch05
(2021) · American Diabetes Association eBooks · doi:10.2337/9781580407625.ch04
Overview of the Epidemiology and Pathophysiology of Diabetes
(2021) · American Diabetes Association eBooks · doi:10.2337/9781580407625.ch01
CURRENT STATUS OF DIABETES TREATMENTS AND UNMET NEEDS
Kanazawa, A. (2012) · Juntendō Igaku/Juntendo igaku · doi:10.14789/pjmj.58.472
Hanson, R. L., Kobes, S., WEDEKIND, L. E., Arreola, E. V., Ramirez-Luzuriaga, M. J., & Hsueh, W. (2026) · BMC Medical Genomics · doi:10.1186/s12920-026-02386-7
“Analyses of prevention studies in the US and Finland suggest that lifestyle intervention is effective for diabetes prevention regardless of PRS, in some cases even in those at low clinical risk, but further studies are needed [60, 61].”
Kana, S. L., & Leivant, M. (2026) · Springer eBooks · doi:10.1007/978-3-031-90919-1_6-1
Wang, X., Shen-tao, W., & Wang, B. (2026) · Current Radiopharmaceuticals · doi:10.1016/j.craph.2026.100073
Raghavan, S., & Lange, L. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00015-9
Metadata
- Authors
- Hivert, M.-F., Jablonski, K. A., Perreault, L., Saxena, R., McAteer, J. B., Franks, P. W., Hamman, R. F., Kahn, S. E., Haffner, S., the DIAGRAM Consortium, Meigs, J. B., Altshuler, D., Knowler, W. C., Florez, J. C., & for the Diabetes Prevention Program Research Group
- Affiliations
- Université de Sherbrooke (CA)
- George Washington University (US)
- University of Colorado Anschutz (US)
- Broad Institute (US)
- Lund University (SE)
- Colorado School of Public Health (US)
- University of Washington (US)
- Baylor College of Medicine (US)
- Harvard University (US)
- National Institutes of Health (US)
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-03-22
- Volume
- 60
- Issue
- 4
- Pages
- 1340-1348
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3064108
- OpenAlex
- W2119445047
- Cited by
- 191
- References
- 36
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 8 · 2021: 13 · 2020: 9 · 2019: 13 · 2018: 10 · 2017: 13 · 2016: 14 · 2015: 17 · 2014: 19 · 2013: 11 · 2012: 30
- FWCI
- 13.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK072041, K24DK080140, P30DK017047)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, polygenic risk score, Diabetes Prevention Program, diabetes incidence, lifestyle intervention, metformin, insulinogenic index, beta-cell function, genetic susceptibility
- MeSH terms
- Diabetes Mellitus, Type 2, Exercise Therapy, Genotype, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Metformin, Weight Loss, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.